

Mice with a Brd4 mutation represent a new model of nephrocalcinosis

Gorvin, Caroline M; Loh, Nellie; Stechman, Michael; Falcone, Sara; Hannan, Fadil M; Ahmad, Bushra; Piret, Sian; Reed, Anita; Jeyabalan, Jeshmi; Leo, Paul; Marshall, Mhairi; Sethi, Siddharth; Bass, Paul; Roberts, Ian; Sanderson, Jeremy; Wells, Sara; Hough, Tertius; Bentley, Liz; Christie, Paul; Simon, Michelle

DOI:
[10.1002/jbmr.3695](https://doi.org/10.1002/jbmr.3695)

License:
Other (please specify with Rights Statement)

Document Version
Peer reviewed version

Citation for published version (Harvard):

Gorvin, CM, Loh, N, Stechman, M, Falcone, S, Hannan, FM, Ahmad, B, Piret, S, Reed, A, Jeyabalan, J, Leo, P, Marshall, M, Sethi, S, Bass, P, Roberts, I, Sanderson, J, Wells, S, Hough, T, Bentley, L, Christie, P, Simon, M, Mallon, A-M, Schulz, H, Cox, R, Brown, M, Huebner, N, Brown, S & Thakker, RV 2019, 'Mice with a Brd4 mutation represent a new model of nephrocalcinosis', *Journal of Bone and Mineral Research*, vol. 34, no. 7, pp. 1324-1335. <https://doi.org/10.1002/jbmr.3695>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:
Checked for eligibility 11/02/2019

This is the peer reviewed version of the following article: Gorvin, C. M., Loh, N. Y., Stechman, M. J., Falcone, S., Hannan, F. M., Ahmad, B. N., Piret, S. E., Reed, A. A., Jeyabalan, J., Leo, P., Marshall, M., Sethi, S., Bass, P., Roberts, I., Sanderson, J., Wells, S., Hough, T. A., Bentley, L., Christie, P. T., Simon, M. M., Mallon, A., Schulz, H., Cox, R. D., Brown, M. A., Huebner, N., Brown, S. D. and Thakker, R. V. (2019), Mice With a Brd4 Mutation Represent a New Model of Nephrocalcinosis. *J Bone Miner Res.* doi:10.1002/jbmr.3695, which has been published in final form at: <https://doi.org/10.1002/jbmr.3695>. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Mice with a Brd4 mutation represent a new model of nephrocalcinosis

Caroline M. Gorvin^{1,a,b} *, Nellie Y. Loh¹ *, Michael J. Stechman¹ *, Sara Falcone¹, Fadi M. Hannan^{1,2}, Bushra N. Ahmad¹, Sian E. Piret^{1,c}, Anita A. C. Reed¹, Jeshmi Jeyabalan¹, Paul Leo³, Mhairi Marshall³, Siddharth Sethi⁴, Paul Bass⁵, Ian Roberts⁶, Jeremy Sanderson⁴, Sara Wells⁴, Tertius A. Hough⁴, Liz Bentley⁴, Paul T. Christie¹, Michelle M. Simon⁴, Ann-Marie Mallon⁴, Herbert Schulz^{7,d}, Roger D. Cox⁴, Matthew A. Brown³, Norbert Huebner⁷, Steve D. Brown⁴ and Rajesh V. Thakker¹

* Authors contributed equally to this work.

AUTHOR AFFILIATIONS:

¹Academic Endocrine Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, UK

²Institute of Ageing and Chronic Disease, University of Liverpool, UK

³Translational Genomics Group, Institute of Health and Biomedical Innovation, School of Biomedical Sciences, Queensland University of Technology (QUT) at Translational Research Institute, Brisbane, Australia

⁴Mary Lyon Centre and Mammalian Genetics Unit, Medical Research Council Harwell Institute, Harwell, UK

⁵Department of Cellular Pathology, Royal Free Hospital, London, UK

⁶Department of Cellular Pathology, John Radcliffe Hospital, Oxford, UK

⁷Max-Delbrück-Center for Molecular Medicine, Robert-Rössle-Str. 10, Berlin, Germany

Current address:

^aInstitute of Metabolism and Systems Research, University of Birmingham, UK

^bCentre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, UK

^cDepartment of Medicine, Stony Brook University, Stony Brook, NY, USA

^dCologne Center for Genomics, Weyertal 115 B, Cologne, Germany

CORRESPONDING AUTHOR: Professor Rajesh V Thakker, Academic Endocrine Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, OX3 7LJ, UK. Email: rajesh.thakker@ndm.ox.ac.uk

DISCLOSURE: RVT received grant funding from NPS/Shire Pharmaceuticals, GlaxoSmithKline, Novartis Pharma AG and the Marshall Smith Syndrome Foundation for unrelated studies. All other authors confirm no conflict of interest.

ABSTRACT

Nephrolithiasis (NL) and nephrocalcinosis (NC), which comprise renal calcification of the collecting system and parenchyma, respectively, have a multi-factorial etiology with environmental and genetic determinants, and affect ~10% of adults by 70 years of age. Studies of families with hereditary NL and NC have identified >30 causative genes which have increased our understanding of extracellular calcium homeostasis and renal tubular transport of calcium. However, these account for <20% of the likely genes that are involved and to identify novel genes for renal calcification disorders we investigated 1,745 12-month old progeny from a male mouse that had been treated with the chemical mutagen, *N*-ethyl-*N*-nitrosourea (ENU), for radiological renal opacities. This identified a male mouse with renal calcification which was inherited as an autosomal dominant trait with >80% penetrance in 152 progeny. The calcification consisted of calcium phosphate deposits in the renal papillae and was associated with the presence of the urinary macromolecules osteopontin and Tamm-Horsfall protein, which are features found in Randall's plaques of patients with NC. Genome-wide mapping located the disease locus to a ~30Mbp region on chromosome 17A3.3-B3 and whole-exome sequence analysis identified a heterozygous mutation, resulting in a missense substitution (Met149Thr, M149T), in the bromodomain containing protein 4 (*BRD4*). The mutant heterozygous (*Brd4*^{+/*M149T*}) mice, when compared to wild-type (*Brd4*^{+/*+*}) mice, were normocalcemic and normophosphatemic, with normal urinary excretions of calcium and phosphate, and had normal bone turnover markers. *BRD4* plays a critical role in histone modification and gene transcription, and cDNA expression profiling, using kidneys from *Brd4*^{+/*M149T*} and *Brd4*^{+/*+*} mice, revealed differential expression of genes involved in vitamin D metabolism, cell differentiation and apoptosis. Kidneys from *Brd4*^{+/*M149T*} mice also had increased apoptosis at sites of calcification within the renal papillae. Thus, our studies have established a mouse model, due to a *Brd4* Met149Thr mutation, for inherited NC.

INTRODUCTION

Renal calcification may occur in the kidney parenchyma (nephrocalcinosis (NC)) or the collecting system (nephrolithiasis (NL), i.e. kidney stones)⁽¹⁻⁴⁾. NL and NC affect ~10% of the adult Western population by the age of 70 years⁽¹⁻³⁾, although such distinctions may be difficult in patients who may develop both NL and NC, and it has been reported that >50-70% of patients with kidney stones will have NC⁽⁵⁾. The renal calcification in NL and NC, results from deposition of calcium oxalate and calcium phosphate⁽⁴⁾, which has a multifactorial etiology that involves environmental and genetic causes, and may also be associated with several endocrine and metabolic disorders including primary hyperparathyroidism, hypercalciuria, renal tubular acidosis, cystinuria, low urinary volume and hyperoxaluria^(1,6). Hypercalciuria is the commonest metabolic abnormality associated with NL and NC; however around 30% of individuals with kidney stones have been reported to have no obvious underlying metabolic defect (idiopathic NL)^(1,6-8). NL, NC and hypercalciuria are likely to have a genetic basis as up to 65% of kidney stone patients have been reported to have an affected family member^(9,10) and twin studies have estimated that the heritability of hypercalciuria⁽¹¹⁾ and kidney stones⁽¹²⁾ is >50% and >55%, respectively. Moreover, studies of families with rare monogenic disorders associated with hypercalciuric NL and NC, such as Bartter's syndrome, Dent's disease, autosomal dominant hypocalcaemia, and distal renal tubular acidosis have identified mutations in >30 genes involved in the regulation of calcium transport (Table S1)^(3,13,14). Furthermore, genome-wide association studies and targeted sequencing of genes with known roles in calcium and vitamin D metabolism have reported associations for NL and NC with common sequence variants in >10 additional genes (Table S1)^(2,15-17). However,

these account for only ~15-20% of cases^(3,13), and the identification of further monogenic causes of NL and NC are limited by the availability of large families. To overcome this and to facilitate further positional cloning studies to discover other genes regulating renal calcification, we undertook an X-ray screen of first generation (G1) offspring of mice treated with the chemical mutagen *N*-ethyl-*N*-nitrosourea (ENU)⁽¹⁸⁾, for renal opacities, with the aim of identifying mice with renal calcium deposits, as calcium-containing stones are the most common type of kidney stones. ENU is an alkylating agent that causes germ-line point mutations with a frequency as high as 0.015 mutations/locus⁽¹⁹⁾. Such mutations may result in loss-of-function, hypomorphic, hypermorphic and dominant-negative changes in protein function, thus making the ENU mouse mutagenesis resource a useful tool for generating novel genetic models of human disease^(18,19). Here, we describe a mouse model for autosomal dominant renal calcification, designated RCALC type 1 (RCALC1), identified from this ENU screen, which is associated with a Met149Thr missense mutation in the gene encoding bromodomain containing protein 4 (*Brd4*).

MATERIALS AND METHODS

Experimental Animals

ENU-treated G0 BALB/cAnNCrl male mice were mated to C3H/HeH (C3H) females to produce G1 progeny. Male G1 offspring were X-rayed for renal opacities and sperm archived, as previously described^(20,21). Archived sperm from the founder male with renal calcification (Fig. 1A) was used for *in vitro* fertilisation (IVF) of C3H oocytes to derive G2 animals for inheritance testing and genetic mapping studies⁽²⁰⁾. Mice were fed on a standard diet (Rat and Mouse number 3, Special Diet Services, Essex, UK) that contained 1.15% calcium, 0.58% phosphate, and 4089 IU/kg of vitamin D, and provided with water *ad libitum*⁽²²⁾. All animal studies were carried out using guidelines issued by the UK Medical Research Council in Responsibility in Use of Animals for Medical Research (July 1993) and UK Home Office project licence numbers (30/2250 and 30/2752).

Metabolic cage studies, plasma and urine biochemistry

Sixteen-week-old G2 mice were individually housed in metabolic cages (Techniplast, Louviers, France) for 5 days with free access to food and water⁽²³⁾. Mice were weighed before and after the study, and food and water intake were monitored. Twenty-four-hour urine samples were collected in the presence of sodium azide and blood samples were collected from lateral tail vein or the internal jugular vein in lithium heparin Microvette tubes (Sarstedt, Leicester, UK) following terminal anaesthesia, as previously described⁽²³⁾. Plasma and/or urine were appropriately analyzed for sodium, potassium, chloride, total calcium, phosphate, urea, glucose, creatinine, magnesium, urate, citrate, total protein, albumin and alkaline phosphatase activity on a Beckman Coulter AU680

analyzer, as previously reported^(21,22). Plasma calcium was adjusted for variations in albumin concentrations using the formula: (plasma calcium (mmol/L) – [(plasma albumin (g/L) – 30) × 0.02]), as reported⁽²²⁾. Plasma PTH was measured using a two-site ELISA specific for mouse intact PTH (Immutopics)⁽²²⁾. Plasma concentrations of 25-hydroxyvitamin D (25OHD) and Procollagen type 1 N-terminal propeptide (P1NP), and also urinary concentrations of serum C-telopeptide (CTX) were measured by enzyme immunoassay (EIA) (Immunodiagnostic Systems)^(24,25). Urine pH was measured using a pH 211 meter (Hanna Instruments)⁽²⁶⁾. A Kruskal-Wallis test was undertaken for multiple comparisons, and any significant differences identified were further assessed using the Dunn's test for nonparametric pairwise multiple comparisons. All analyses were undertaken using GraphPad Prism software, and a value of $p < 0.05$ was considered significant.

Kidney histology and immunofluorescence

Kidneys were dissected from 16-18 week old mice, halved, fixed in 10% neutral-buffered formalin overnight, and embedded in paraffin wax. Four- μ m serial sections were prepared and stained with haematoxylin and eosin (H&E), and von Kossa, which reacts with the phosphate moiety of calcium phosphate⁽²⁷⁾, as described previously⁽²⁰⁾. Images were collected on a Nikon Eclipse E400 microscope (Kingston-upon-Thames, UK), equipped with a Nikon DXM1200C digital camera. Slides were examined by two independent observers, by light microscopy using 10x and 20x objective lenses to confirm the presence of renal calcification. Each observer was blinded to the experimental group and in cases in which there was disagreement a third investigator

reviewed the slide and made the final decision. Coincident calcification on at least two serial sections was accepted as positive, and the H&E stained sections were then examined under polarized light for possible birefringence, that would indicate the presence of calcium oxalate crystals in the depositions⁽²⁷⁾, using a Zeiss Axiocam MRc (Cambridge, UK) camera, with a pixel size of 6.7 μm and a 1300 x 1030 pixel field of view equivalent to an area of 8.7 mm x 6.9 mm, that was adapted for polarised light microscopy with plan semi-apochromat 10x/NA 0.3 and 20x/NA 0.35 LWD objectives.

Pizzolato staining to detect calcium oxalate was performed as described⁽²⁸⁾. Briefly, 4 μm kidney serial sections were deparaffinised, rehydrated, then incubated in a solution of equal quantities of 5% silver nitrate and 30% hydrogen peroxidase under a 60-watt light bulb. Sections were then counterstained with nuclear fast red. Osteopontin immunohistochemistry was performed on deparaffinised, rehydrated 4 μm kidney sections following antigen retrieval using an anti-osteopontin rabbit polyclonal antibody (L-175, kind gift from LW Fisher, NIH, Maryland, USA)⁽²⁹⁾, followed by an Alexa Fluor 488-conjugated donkey anti-rabbit antibody (Molecular Probes, Hilden, Germany). Tamm-Horsfall protein (THP) staining was performed using sheep anti-THP (Biodesign International, Maine, USA), followed by a secondary detection using Cy3-conjugated donkey anti-sheep antibody (Jackson ImmunoResearch, Newmarket, UK). Controls were performed without a primary antibody, and showed no staining.

Terminal deoxynucleotidyl transferase dUTP nick end-labelling (TUNEL) to detect apoptotic cells was performed using the ApopTag Fluorescein *In Situ* Apoptosis Detection kit (Millipore, Watford, UK) according to the manufacturer's instructions.

Stained sections were mounted in Vectashield containing DAPI (Vector Labs, Peterborough, UK) visualised by epifluorescence microscopy and a Nikon DXM1200C digital camera. The NIS-Elements BR 2.30 software was used to estimate the number of TUNEL positive cells per 1000 DAPI positive cells. Statistical comparisons for TUNEL staining was performed using the Fisher's exact test and χ^2 test with Yate's correction.

Genetic Mapping

Genomic DNA was isolated from tail biopsies using the Genra PureGene kit (Qiagen, Manchester, UK) and genome-wide scans performed by pyrosequencing⁽³⁰⁾ using a panel of 59 informative SNPs distributed across 19 autosomes, at 20-30cM intervals. Polymorphic positions were analyzed using a PSQ-96 system (Qiagen)⁽²⁰⁾. Chromosomal linkage was verified by non-inheritance of BALB/c alleles of SNPs of interest in 13 unaffected littermates. G2 and G3 mice were genotyped for additional markers within the critical region.

Exome sequence analysis

Sequencing libraries were constructed using the NimbleGen kit (Roche, West Sussex, UK) and libraries combined in pools of six for targeted capture, using the SeqCap EZ Mouse Exome SR v2.2 (target regions available from ftp://ftp.jax.org/Genome_Biology_mouse_exomes). Libraries were assessed pre- and post-capture for quality and yield, using a High Sensitivity DNA assay (Agilent, Santa Clara, California) and Library Quantification Kit (Kapa Biosystems, Gillingham, UK). Massive parallel sequencing was performed with 6 samples per flow cell lane, using the

HiSeq2000 platform and SBS reagents (Illumina, San Diego, California) to generate 100bp paired-end reads. Illumina Data Analysis Pipeline software (CASAVA 1.8.1) was used for initial base calling and data multiplexing. Illumina reads were mapped to the mouse genome (mm9) using the Burrows-Wheeler Aligner (BWA)_v2⁽³¹⁾ with the default parameters. Single nucleotide variant (SNV) calls were made using a customised version of The Genome Analysis Toolkit (GATK)⁽³²⁾ with default parameters. Several triaging steps were made to reduce false positives⁽³³⁾. The 17 Mouse Genome dataset⁽³⁴⁾ was used to filter inbred single nucleotide polymorphism (SNPs) sites from the RCALC1 SNV dataset, and common sites were removed from further investigation. The remaining SNVs were further filtered by removing sites with an allele frequency <35% and >80%, a read depth <3 and a quality score <200. The final RCALC1 SNV dataset was annotated with NGS-SNP⁽³⁵⁾.

DNA sequence analysis, protein sequence alignment and protein prediction

Variants were validated in G2 mice by Sanger DNA sequencing, using appropriate gene-specific primers (Sigma, Gillingham, UK), followed by dideoxynucleotide sequencing using the BigDye Terminator v3.1 Cycle Sequencing Kit (Life Technologies, Carlsbad, California) and an automated detection system (ABI3730 capillary sequencer; Applied Biosystems, Carlsbad, California)⁽³⁶⁾. Protein sequences were aligned using ClustalW⁽²⁰⁾. MutationTaster (<http://www.mutationtaster.org/>) was used to predict the effects of mutations⁽³⁷⁾. BRD4 modeling was undertaken using the BRD4 structure in complex with an extracellular signal-regulated kinase 5 inhibitor (PDB: 5LRQ), and figures prepared using the PyMOL Molecular Graphics System, Schrodinger (<https://pymol.org/>).

RNA extraction, cDNA Expression Profiling and quantitative RT-PCR (qRT-PCR)

Total RNA was extracted from whole kidney samples taken from >16 week-old RCALC1, or parental wild-type (WT) BALB/c and C3H mice (N= 4 mice per group) using Trizol reagent (Invitrogen, Carlsbad, CA). Following DNaseI-treatment, RNA was purified using an RNeasy Mini kit (Qiagen). Nine- μ g total RNA was used for first and second-strand cDNA synthesis using the One-Cycle cDNA Synthesis Kit (Affymetrix, High Wycombe, UK) according to the manufacturer's instructions. Biotinylated cRNA was synthesized using the Genechip IVT Labelling Kit (Affymetrix). Fifteen- μ g of fragmented cRNA was hybridized for 16 hours at 45°C to Mouse Genome 430 2.0 arrays (Affymetrix). Following hybridization, arrays were washed and stained with streptavidin-phycoerythrin in the Affymetrix Fluidics Station 450 and scanned using the GeneChip Scanner 3000 7G. The image data were analyzed with GCOS 1.4 using Affymetrix default analysis settings and global scaling as a normalization method. The dataset of the arrays were normalized using Robust Multi-chip Average algorithm in respect to the sequence-specific probe affinities⁽³⁸⁾. Probesets with marginal expression (maximum native signal <50) were removed and the remaining 17,811 probe sets were analyzed using the F-test. After ANOVA false discovery rate (FDR) multiple testing corrections⁽³⁹⁾, individual differences between the datasets were investigated using the least significant difference (LSD) posthoc test. Genes with >1.5-fold difference in expression (in the same direction) vs. both parental strains were selected for further investigation. qRT-PCR reactions were performed in kidney samples from 4-5 mice using the QuantiTect SYBR Green Kit (Qiagen) and a Rotorgene 5 (Qiagen), as previously

described⁽⁴⁰⁾. All qRT-PCR test samples were normalized to the geometric mean of three housekeeper genes (cyclin D1 (*Ccnd1*), cyclin D2 (*Ccnd2*), and glyceraldehyde 3-phosphate dehydrogenase (*Gapdh*)), as described previously⁽⁴⁰⁾. All primers were obtained from Quantitect (Qiagen). Threshold cycle (C_T) values were obtained from the start of the log phase on Rotorgene Q Series Software and C_T values analyzed in Microsoft Excel 97–2010 using the Pfaffl method^(40,41). Data for RCALC1 mice were expressed relative to wild-type littermates, which were set at 1. Statistical analyses were performed using the Student's t-test.

Statistical analysis

Statistical analyses were performed using the Kruskal-Wallis test, Dunn's test for nonparametric pairwise multiple comparisons, Fisher's exact test, χ^2 test with Yate's correction, Student's t-test, the F-test, and LSD posthoc tests.

RESULTS

Identification and characterization of mice with autosomal dominant renal calcification (RCALC1)

A radiological screen of 1,745 12-month old G1 male offspring of ENU-treated BALB/c males and wild-type (WT) C3H/HeH (C3H) females was performed to detect renal opacities. This identified a male with a single opacity in the region of the left kidney (Fig. 1A). To confirm genetic transmission of the phenotype of renal calcification, 152 second-generation (G2) backcross mice (69 males, 83 females) were derived by *in vitro* fertilisation (IVF) of WT C3H oocytes using sperm archived from this founder G1 male with renal calcification. These G2 mice were assessed at 16-18 weeks of age by renal histology, as renal opacities could not be detected by X-ray in mice of this age range. Renal histology was performed using sections stained with H&E (Fig. S1) and von Kossa stain (Fig. 1B-E), which specifically reacts with the phosphate moiety of calcium phosphate deposits⁽²⁷⁾, and polarized light microscopy to assess for birefringence due to calcium oxalate crystals (Fig. S1). This approach was used as calcium phosphate and calcium oxalate crystals can be distinguished by their tinctorial properties⁽²⁷⁾. Thus, on H&E stained sections, calcium phosphate deposits may appear blue or purple (Fig. S1), whereas calcium oxalate deposits are translucent; whilst sections treated with von Kossa stains reveal calcium phosphate, but not calcium oxalate crystals as dark brown or black deposits (Fig. 1B-E, Fig. S1); whereas only calcium oxalate, but not calcium phosphate, crystals are birefringent under polarized light⁽²⁷⁾. This analysis showed that the renal calcification in the G2 mice consisted of calcium phosphate, as the deposits were: blue-purple on H&E sections (Fig. S1); and deep brown-black on von Kossa stained sections

(Fig. 1B-C and Fig. S1). Moreover, the renal calcification was not birefringent under polarized light (Fig. S1), thereby indicating that it did not contain calcium oxalate crystals, and this was confirmed by use of Pizzolato staining and observing a lack of brown-black deposits⁽²⁸⁾ (Fig. S1).

The calcification, due to calcium phosphate deposits was observed to occur in the renal cortex and papilla of the G2 mice (Fig. 1B-C). However, spontaneous renal calcification has been reported to occur in WT C3H mice^(42,43), and to minimise confounding influences on the phenotype of renal calcification from the WT C3H strain we further characterized the locations of the renal calcification by von Kossa staining using kidney sections from WT C3H mice at 16 weeks of age (10 males, 10 females). In the WT C3H mice, the renal calcification was found to be present within the cortex of all 20 pairs of kidneys, but calcification within the renal papilla was found to be present in only one mouse (i.e. 5% of mice) (Fig. 1D-E). This calcification in the renal papilla of the WT C3H mouse was identified within the intracellular compartment of collecting duct cells (Fig. 1E). Therefore, G2 mice with calcification of the renal cortex or intracellular collecting duct cells were classified as being unaffected, as the calcification was not different to that observed in the WT C3H mice, and G2 mice having renal calcification specifically within the interstitial regions of the renal papilla (Fig. 1C), were classified as having the RCALC1 phenotype. Using these criteria, seventy (26 males, 44 females) of the 152 G2 mice (i.e. 46%) were found to have calcification within the interstitial regions of the renal papilla, consistent with an autosomal dominant disorder, in which ~50% of progeny would be affected. In addition, the ratio of affected males to affected females

was not significantly different to the expected 1:1 ratio of affected males (M) and females (F) (i.e. 26M:44F versus 35M:35F, χ^2 -test, $p=0.125$) for an autosomal dominant disorder. The ratio of WT (i.e. unaffected) males:females = 39M to 43F was also not significantly different to the expected 1:1 ratio (i.e. 41M:41F, χ^2 -test, $p=0.871$), for an autosomal dominant trait.

The RCALC1 phenotype has similarities to human NC, which includes the interstitial deposition of calcium phosphate in the renal papillae^(4,44,45). For example, high resolution Fourier transform infrared microspectroscopy and electron diffraction studies have revealed that calcium phosphate crystals are the major component of Randall's plaque, which are the areas of the renal papillae that contain interstitial calcium phosphate deposits that provide a nidus of urothelial surface for calcium oxalate deposition^(4,6,16,46,47). Moreover, immunohistological examinations of renal biopsies from patients with kidney stones, have shown the presence of the urinary macromolecules osteopontin and THP in association with Randall's plaques^(44,45,48), and to explore the similarities between the RCALC1 and human NC histological phenotypes, we therefore investigated serial sections of kidneys from the RCALC1 mice and WT littermates for such abnormalities using immunofluorescence to detect osteopontin and THP, and von Kossa staining to detect calcification. This revealed the presence of osteopontin in the areas of interstitial calcification within the renal papillae of RCALC1 mice (Fig. 1F-G), and this was absent in the renal papillae of WT littermates (Fig. 1H-I) ($n=4$; 2-tailed Fisher's Exact test, $p<0.01$). Moreover, THP, which was found to be present in the thick ascending limb of Henle in RCALC1 and WT kidneys (Fig. 1J and 1L), was also

localised to the interstitial space of the renal papilla in RCALC1 mice (Fig. 1J) where it colocalized with calcified areas that were revealed by von Kossa staining (Fig. 1J-K). Interstitial THP immunostaining was not detected in the renal papilla of WT mice (Fig. 1L-M). Therefore, RCALC1 mice have calcification **due to calcium phosphate deposition** of the renal papilla, which contains osteopontin and THP, **and these findings are similar to those observed in patients with NC^(4,46)**.

Mapping of the *RCALC1* locus to chromosome 17A3.3-B3 and identification of the *Brd4* missense mutation by whole-exome sequence analysis

Genome-wide analysis using a panel of 59 informative SNPs and DNA from 13 G2 mice with renal papillary calcification (i.e. the RCALC1 phenotype) mapped the *RCALC1* locus to a ~30Mbp region on chromosome 17 A3.3-B3 between *rs33663699* and *D17Mit115* (LOD=3.91, 0% recombination) (Fig. 2A). Further mapping studies using 11 additional genetic markers (8 microsatellite markers and 3 SNPs) within this candidate interval in an additional 38 G2 RCALC1 mice (total number of 51 mice studied) revealed the renal calcification phenotype co-segregated with BALB/c alleles between *rs33663699* and *D17Mit51* (Fig. 2A). Co-segregation of the RCALC1 phenotype with markers in this chromosome 17A3.3-B3 interval was confirmed in up to 4 generations. Finally, 26 of the 152 G2 mice (i.e. 17%), with the BALB/c haplotypes for the chromosome 17 markers, were phenotypically normal (i.e. did not have renal papillary calcification), thereby indicating an 83% penetrance for this phenotype in >16 week-old G2 mice.

The interval between *rs33663699* and *D17Mit115* that encompasses the *RCALC1* locus contains over 500 genes, and to identify the RCALC1 causative gene, we performed

whole-exome sequence analysis in two G2 RCALC1 mice with renal papillary calcification, as well as one WT BALB/c mouse and one WT C3H mouse, in order to determine inheritance of the variants from the parental mice. This analysis identified 20 unique variants, of which three were located on chromosome 17, but only one of these, which involved the bromodomain containing protein 4 (*Brd4*) gene, was within the interval containing the *RCALC1* locus (Table S2). This variant was a non-synonymous heterozygous T-to-C transition at nucleotide c.446 in the *Brd4* gene. The T-to-C transition in codon 149 of *Brd4* is predicted to cause a missense amino acid change from Met149 to Thr149 (Met149Thr, M149T) (Fig. 2B). Further analysis of the G2 mice (total = 152), by Sanger DNA sequencing (Fig. 2B), revealed that 66% of the mice with renal papillary calcification were heterozygous for the *Brd4* variant (*Brd4*^{+/*M149T*}), and 74% of mice without renal papillary calcification were homozygous for the WT allele (*Brd4*^{+/*+*}) (Table 1). Extension of the co-segregation analysis to the G3 (n=62), G4 (n=31) and G5 (n=55) mice revealed that: 65% of G3, 100% of G4 and 83% of G5 mice with renal papillary calcification were *Brd4*^{+/*M149T*}, consistent with RCALC1 being an autosomal dominant disorder with reduced penetrance and likely due to a BRD4 mutation (Table 1). The effects of the BRD4-Met149Thr mutation on protein structure were therefore assessed in further detail.

Characterization of the BRD4-Met149Thr variant on protein structure

To assess the potential pathogenicity of the BRD4-Met149Thr variant we first examined online databases containing sequencing data from exome analysis in mice and humans. The BRD4-Met149Thr variant was absent from mouse populations, assessed using The

Jackson Laboratory database of exome sequencing data from 175 strains of mice⁽⁴⁹⁾, and human populations, assessed using the exome aggregation browser (ExAc), which contains genetic information on 60,706 individuals⁽⁵⁰⁾, thereby indicating that the BRD4 Met149Thr variant is not a common polymorphism. The BRD4 Met149 residue is also highly evolutionarily conserved (Fig. 2C) and bioinformatic analysis using MutationTaster software⁽³⁷⁾ predicted the BRD4-Met149Thr variant to be damaging. We therefore next assessed the effect of the BRD4-Met149Thr variant on BRD4 protein structure. The BRD4 protein plays a critical role in transcriptional activation by binding to acetylated histone tails using its tandem bromodomains (BD) BD1 and BD2, and regulates transcription by recruiting proteins involved in nuclear remodelling using its extraterminal (ET) domain and its C-terminal interaction motif (CTM) (Fig. 2D)⁽⁵¹⁻⁵⁴⁾. The Met149 residue is located in the α C-helix of BRD4 BD1 (Fig. 2E), and previous studies have shown that Met149 is critical for histone binding, and that mutation to Ala149 impairs this binding⁽⁵⁵⁾. Structural modelling showed that the Met149 residue forms critical backbone contacts with three residues within α C (Fig. 2F), and likely plays a pivotal role in maintaining the structural integrity of BD1. Mutation to Thr149 is predicted to retain these contacts and form an additional polar contact with Asp145 (Fig. 2G), which may reduce the flexibility of BD1. Thus, the BRD4-Met149Thr variant is likely to affect protein structure, and we therefore assessed the metabolic phenotype of mice with this mutation in further detail.

Metabolic phenotype analysis of mice with the BRD4-Met149Thr mutation

Renal calcification is often associated with metabolic abnormalities including hypercalciuria, and we therefore performed biochemical analyses of plasma and urine samples from WT (*Brd4*^{+/+}) and heterozygous mutant *Brd4* (*Brd4*^{+/*M149T*}) mice^(1,6,7,56). *Brd4*^{+/*M149T*} mice were fertile, grew at similar rates as their *Brd4*^{+/+} littermates, had similar body weights, and appeared morphologically normal. Analyses of plasma and urine samples from *Brd4*^{+/+} and *Brd4*^{+/*M149T*} adult mice, aged 16 weeks, revealed no significant differences between *Brd4*^{+/+} and *Brd4*^{+/*M149T*} mice in plasma concentrations of sodium, potassium, albumin-adjusted calcium, chloride, urea, creatinine, glucose, phosphate, alkaline phosphatase activity, PTH or 25OHD (Table 2). Furthermore, there were no significant differences between *Brd4*^{+/+} and *Brd4*^{+/*M149T*} mice in urine output or pH (Table 3). There were also no significant differences in the urinary excretion of calcium, phosphate, sodium, potassium, magnesium, urate, citrate or protein, which have previously been associated with renal calcification⁽⁵⁷⁾ (Table 3). An assessment of bone turnover showed no significant differences in plasma PINP or urine CTx concentrations (Tables 2 and 3). Therefore, RCALC1 is a representative model for idiopathic renal calcification with no associated biochemical abnormality.

Effect of the BRD4-Met149Thr mutation on gene transcription

BRD4 plays a critical role in histone modification and gene transcription, and previous studies have shown that the Met149 residue is important for histone binding⁽⁵⁵⁾. We therefore hypothesised that the *Brd4*^{+/*M149T*} mutation may lead to changes in gene transcription, which may explain the renal calcification phenotype observed in RCALC1 mice. To assess gene transcription, we performed cDNA expression profiling using

whole kidneys from four *Brd4*^{+/*M149T*} and eight *Brd4*^{+/*+*} mice from the parental strains (4 BALB/c mice and 4 CH3 mice). We used kidneys as it was not possible to use microdissected specimens of calcified regions from the papilla, as these calcified regions had a mean diameter of 30.56µm (range 8 - 70µm) (sections from n = 63 mice), and the mean area of calcification was 725.83µm² (range 50.24 – 3846.5 µm²), and therefore too small to extract high-quality RNA that would allow for the cDNA expression profiling studies. These analyses of kidneys revealed 37 genes to be significantly differentially expressed by at least 1.50-fold in *Brd4*^{+/*M149T*} mice, when compared to *Brd4*^{+/*+*} mice (Table S3 and Table S4). Eighteen genes were significantly upregulated and 19 genes significantly downregulated in *Brd4*^{+/*M149T*} kidneys, when compared to *Brd4*^{+/*+*} kidneys (Table S3 and S4). This included two genes involved in regulating vitamin D₃ and calcium homeostasis. Thus, the vitamin D₃-24-hydroxylase transcript cytochrome P450, family 24, subfamily A, polypeptide 1 (*Cyp24a1*), which encodes the 24-hydroxylase enzyme that degrades active 1,25-dihydroxyvitamin D₃ to inactive vitamin D metabolites, was 5.05-fold higher in *Brd4*^{+/*M149T*} kidneys, when compared with *Brd4*^{+/*+*} kidneys; whereas expression of the vitamin D binding protein (*Gc*, group-specific component) was 1.55-fold lower in *Brd4*^{+/*M149T*} kidneys, when compared to *Brd4*^{+/*+*} kidneys. Furthermore, qRT-PCR in kidneys from four *Brd4*^{+/*+*} and four *Brd4*^{+/*M149T*} mice confirmed these results (Fig. 3A-B), thereby supporting the role of disturbed vitamin D metabolism in the etiology of the renal calcification observed in RCALC1 mice.

A number of genes involved in cell survival and differentiation were also found to be differentially expressed in *Brd4*^{+/*M149T*} kidneys, when compared to *Brd4*^{+/*+*} kidneys

(Table S3 and S4). The inhibitor of DNA binding 1 (*Id1*) and 3 (*Id3*) genes, which play a role in cell differentiation, were downregulated in *Brd4*^{+/*M149T*} kidneys compared to *Brd4*^{+/*+*} (-3.91-fold for *Id1* and -3.24-fold for *Id3*) (Table S3 and S4, Fig. 3C-D). In addition, genes involved in apoptosis were also differentially expressed. The gene encoding the pro-apoptosis protein caspase 3 (*Casp3*) was upregulated by 1.64-fold, while the cysteine-serine-rich nuclear protein 3 (*Csrnp3*), which is thought to have a role in transforming growth factor (TGF)- β -induced apoptosis⁽⁵⁸⁾ was downregulated by 1.60-fold in *Brd4*^{+/*M149T*} kidneys, when compared to *Brd4*^{+/*+*} kidneys (Table S3 and S4, Fig. 4A-B). Previous studies of cultured renal cells and rat models of NL have suggested that apoptosis promotes adhesion and retention of calcium containing crystals⁽⁵⁹⁻⁶¹⁾, and because we had observed changes in expression of genes that are known to be important in apoptosis, we further sought to determine whether increased apoptosis was present in *Brd4*^{+/*M149T*} kidneys. Apoptosis was assessed in serial sections from kidneys of *Brd4*^{+/*M149T*} and *Brd4*^{+/*+*} mice using TUNEL staining, and von Kossa staining (Fig. 4C-F). The percentage of apoptotic nuclei in the renal papillae of *Brd4*^{+/*M149T*} mice (n=7) was not significantly different to that observed in *Brd4*^{+/*+*} mice (n=4) (1.13% \pm 0.33% vs. 3.36% \pm 1.24%, respectively, t-test p>0.1). However, in 3 of the 7 kidneys from *Brd4*^{+/*M149T*} mice examined, TUNEL-labelling was observed in interstitial regions of the renal papilla corresponding to sites of calcification (Fig. 4C, E), consistent with apoptosis of interstitial cells, which may comprise renal fibroblasts and immune cells⁽⁶²⁾. Such labelling was absent in the renal papillae of WT (*Brd4*^{+/*+*}) mice (Fig. 4D, F). Therefore, *Brd4*^{+/*M149T*} mice likely have increased apoptosis at sites of calcification within the renal papilla.

DISCUSSION

Our studies have established a mouse model for an autosomal dominant form of renal calcification, designated RCALC1, which is due to a heterogeneous germline Met149Thr mutation of *Brd4* and has phenotypic similarities to those observed in patients with NC⁽⁴⁾. Thus, RCALC1 mutant mice (*Brd4*^{+/*M149T*}) had the interstitial renal papillary calcium deposits that were similar to the papillary calcification that accompanies Randall's plaque, a lesion observed in 85-95% of humans with calcium phosphate (apatite) and calcium oxalate deposits^(4,5,46). Thus, in humans, Randall's plaque have been reported to contain interstitial apatite deposits that act as a nidus for urothelial surface deposition of calcium oxalate^(4,45), although calcium oxalate has been reported to overlie and adhere to Randall's plaque in only 50% of stone formers⁽⁴⁷⁾. In addition, previous studies of plaque formation in patients with recurrent stones have demonstrated that most stones grow by remaining attached to papillae and that subsequent crystal deposition involves the stone-tissue interface becoming overlaid with osteopontin and THP^(4,44,46). This is consistent with observations that osteopontin is involved in the formation of organic layers of the plaques⁽⁴⁵⁾, and that molecules from the urine, such as THP, attach to these sites and extend the stone into the urinary space⁽⁴⁴⁾. Our findings that the RCALC1 (*Brd4*^{+/*M149T*}) mice have calcification, detected by von Kossa staining, at the interstitial renal papilla that is colocalised with osteopontin and THP (Fig. 1), indicate that renal calcification in the *Brd4*^{+/*M149T*} mice may involve a Randall's plaque-like origin, similar to that observed in humans with NC^(4,45). Thus, our findings suggest that the RCALC1 mutant mouse may represent a model for NC. Moreover, the RCALC1 mutant mice have similarities with other mouse models of NC, which also have interstitial papillary calcification, and these

include mice null for THP^(63,64), osteopontin⁽⁶³⁾, and the sodium-hydrogen exchanger regulator factor 1 (NHERF1)⁽⁶⁵⁾. Furthermore, the absence of plasma and urinary biochemical abnormalities in the RCALC1 mice is also similar to that reported in osteopontin-null mice⁽⁶³⁾, whilst the lack of calcium oxalate deposits at the sites of papillary calcification in the RCALC1 mice is similar to that reported in the THP^(63,64), osteopontin⁽⁶³⁾ and NHERF1⁽⁶⁵⁾ knockout mice. Thus, the RCALC1 mice, which have a *Brd4* mutation, provide another model for studying the process of calcification in Randall's plaques, that is observed in patients with NC^(4,45).

Our results, showing that a *Brd4* mutation (Met149Thr) is associated with renal calcification in the RCALC1 mice, also reveal a new pathogenic role for the encoded protein, BRD4, which plays a critical role in regulating gene transcription by binding to modified histone tails of chromosomal DNA, and recruiting transcriptional activating proteins⁽⁵¹⁻⁵⁴⁾. Our structural studies demonstrated that mutation of Met149 to Thr149 is likely to affect protein structure (Fig. 2), and previous studies have shown the Met149 residue to be required for histone binding⁽⁵⁵⁾. Furthermore, Met149 is highly conserved (Fig. 2), and the Thr149 mutation of this residue has not previously been identified in exome datasets from humans or mice, and co-segregates with the renal calcification phenotype. It is therefore likely that the mutation is pathogenic and is causative for the renal calcification in RCALC1 mice. Moreover, our cDNA expression profiling results showed that the BRD4-Met149Thr mutation resulted in altered expression of *Cyp24a1* and *Gc*, which are key genes in vitamin D metabolism and whose dysregulation in the kidneys (Fig. 3) may result in intracellular effects that cause renal calcification without

altering systemic calcium homeostasis (Table 2-3), as observed to occur in some patients with NC⁽⁴⁾. Such underlying mechanisms that may cause renal calcification, without altering systemic calcium homeostasis, include cell survival, differentiation and apoptosis, and our cDNA expression profiling studies revealed: decreased expression of *Id1* and *Id3* (Fig. 3C-D), which have roles in cell differentiation; and altered expression of *Casp3* and *Csrnp3* (Fig. 4A-B), which have roles in apoptosis. Indeed, our studies of RCALC1 mice demonstrated that kidneys from the *Brd4*^{+M149T} mice had apoptosis of renal papillary interstitial cells in association with the calcified lesions (Fig. 4C-D). These results are consistent with those from other studies that have reported an increased apoptosis and differential expression of genes involved in proliferation in Randall's plaques from stone formers when compared to a control group of patients⁽⁴⁸⁾. Furthermore, stone formation in rats is reported to be associated with an increase in apoptosis, and studies in renal cells have also shown that calcium phosphate stones are associated with apoptosis and changes in cell proliferation^(48,66,67). Thus renal injury, and cell death may be common mechanisms in the etiology of renal calcification and the resulting NC and NL by generating sites that promote calcium crystal aggregation and growth^(59,68).

On the basis of these findings, we propose the following possible model for the interstitial renal papillary calcification and likely NC in RCALC1 mice. In the RCALC1 *Brd4*^{+M149T} mice, the BRD4-Met149Thr mutation will impair gene transcription by affecting histone binding, which results in aberrant expression of genes encoding proteins involved in cell survival and differentiation that are known to be reliant on histone

modification⁽⁵³⁾. Failure of these pathways leads to increased apoptosis in renal papillary cells, and promotes tissue damage resulting in crystal retention and NC. In addition, dysregulation of the vitamin D metabolism pathway may result in intracellular toxic effects that exacerbate apoptosis⁽⁶⁹⁾. In summary, the RCALC1 mouse, which is associated with a BRD4 missense mutation, represents a model of idiopathic renal calcification that provides an *in vivo* resource for mechanistic studies of NC.

ACKNOWLEDGEMENTS

We would like to thank Kumudika Gibson, Michelle Stewart, Terry Hacker, Caroline Barker, Anita Muller, Gabi Born, and Stefan Amisten for their technical support.

This research was funded by: the European Union, EuReGene FP6 (NYL, SEP, LB, RDC, RVT); the Medical Research Council UK (CMG, AACR, JJ, LB, PTC, TAH, RDC, SDB, RVT, grant numbers G9825289 and G1000467); Kidney Research UK (MJS, RVT); the Wellcome Trust (NYL, AACR, BNA, RVT); the University of Oxford (NYL); and a Wellcome Trust Investigator Award (RVT).

REFERENCES

1. Scheinman SJ. Nephrolithiasis. *Semin Nephrol.* 1999;19(4):381-8.
2. Oddsson A, Sulem P, Helgason H, Edvardsson VO, Thorleifsson G, Sveinbjornsson G, et al. Common and rare variants associated with kidney stones and biochemical traits. *Nat Commun.* 2015;6:7975.
3. Halbritter J, Baum M, Hynes AM, Rice SJ, Thwaites DT, Gucev ZS, et al. Fourteen monogenic genes account for 15% of nephrolithiasis/nephrocalcinosis. *Journal of the American Society of Nephrology: JASN.* 2015;26(3):543-51.
4. Shavit L, Jaeger P, Unwin RJ. What is nephrocalcinosis? *Kidney Int.* 2015;88(1):35-43.
5. Bhojani N, Paonessa JE, Hameed TA, Worcester EM, Evan AP, Coe FL, et al. Nephrocalcinosis in Calcium Stone Formers Who Do Not have Systemic Disease. *J Urol.* 2015;194(5):1308-12.
6. Coe FL, Evan A, Worcester E. Kidney stone disease. *J Clin Invest.* 2005;115(10):2598-608.
7. Frick KK, Bushinsky DA. Molecular mechanisms of primary hypercalciuria. *Journal of the American Society of Nephrology : JASN.* 2003;14(4):1082-95.
8. Pak CY. Nephrolithiasis. *Curr Ther Endocrinol Metab.* 1997;6:572-6.
9. Polito C, La Manna A, Nappi B, Villani J, Di Toro R. Idiopathic hypercalciuria and hyperuricosuria: family prevalence of nephrolithiasis. *Pediatr Nephrol.* 2000;14(12):1102-4.
10. Resnick M, Pridgen DB, Goodman HO. Genetic predisposition to formation of calcium oxalate renal calculi. *N Engl J Med.* 1968;278(24):1313-8.
11. Hunter DJ, Lange M, Snieder H, MacGregor AJ, Swaminathan R, Thakker RV, et al. Genetic contribution to renal function and electrolyte balance: a twin study. *Clin Sci (Lond).* 2002;103(3):259-65.
12. Goldfarb DS, Fischer ME, Keich Y, Goldberg J. A twin study of genetic and dietary influences on nephrolithiasis: a report from the Vietnam Era Twin (VET) Registry. *Kidney Int.* 2005;67(3):1053-61.
13. Braun DA, Lawson JA, Gee HY, Halbritter J, Shril S, Tan W, et al. Prevalence of Monogenic Causes in Pediatric Patients with Nephrolithiasis or Nephrocalcinosis. *Clinical journal of the American Society of Nephrology : CJASN.* 2016;11(4):664-72.
14. Daga A, Majmundar AJ, Braun DA, Gee HY, Lawson JA, Shril S, et al. Whole exome sequencing frequently detects a monogenic cause in early onset nephrolithiasis and nephrocalcinosis. *Kidney Int.* 2018;93(1):204-13.
15. Mohebbi N, Ferraro PM, Gambaro G, Unwin R. Tubular and genetic disorders associated with kidney stones. *Urolithiasis.* 2017;45(1):127-37.
16. Oliveira B, Kleta R, Bockenhauer D, Walsh SB. Genetic, pathophysiological, and clinical aspects of nephrocalcinosis. *American journal of physiology Renal physiology.* 2016;311(6):F1243-F52.
17. Thorleifsson G, Holm H, Edvardsson V, Walters GB, Styrkarsdottir U, Gudbjartsson DF, et al. Sequence variants in the CLDN14 gene associate with kidney stones and bone mineral density. *Nat Genet.* 2009;41(8):926-30.

18. Nolan PM, Peters J, Strivens M, Rogers D, Hagan J, Spurr N, et al. A systematic, genome-wide, phenotype-driven mutagenesis programme for gene function studies in the mouse. *Nat Genet.* 2000;25(4):440-3.
19. Noveroske JK, Weber JS, Justice MJ. The mutagenic action of N-ethyl-N-nitrosourea in the mouse. *Mamm Genome.* 2000;11(7):478-83.
20. Loh NY, Bentley L, Dimke H, Verkaart S, Tammaro P, Gorvin CM, et al. Autosomal dominant hypercalciuria in a mouse model due to a mutation of the epithelial calcium channel, TRPV5. *PloS one.* 2013;8(1):e55412.
21. Gorvin CM, Ahmad BN, Stechman MJ, Loh NY, Hough TA, Leo P, et al. An N-Ethyl-N-Nitrosourea (ENU)-Induced Tyr265Stop Mutation of the DNA Polymerase Accessory Subunit Gamma 2 (Polg2) Is Associated With Renal Calcification in Mice. *J Bone Miner Res.* 2018.
22. Hannan FM, Walls GV, Babinsky VN, Nesbit MA, Kallay E, Hough TA, et al. The Calcilytic Agent NPS 2143 Rectifies Hypocalcemia in a Mouse Model With an Activating Calcium-Sensing Receptor (CaSR) Mutation: Relevance to Autosomal Dominant Hypocalcemia Type 1 (ADH1). *Endocrinology.* 2015;156(9):3114-21.
23. Stechman MJ, Loh NY, Thakker RV. Genetic causes of hypercalciuric nephrolithiasis. *Pediatr Nephrol.* 2009;24(12):2321-32.
24. Cluse ZN, Fudge AN, Whiting MJ, McWhinney B, Parkinson I, O'Loughlin PD. Evaluation of 25-hydroxy vitamin D assay on the immunodiagnostic systems iSYS analyser. *Ann Clin Biochem.* 2012;49(Pt 2):159-65.
25. Thrailkill KM, Clay Bunn R, Nyman JS, Rettiganti MR, Cockrell GE, Wahl EC, et al. SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA/2J male mice. *Bone.* 2016;82:101-7.
26. Piret SE, Olinger E, Reed AAC, Nesbit MA, Hough TA, Bentley L, et al. A mouse model for inherited renal fibrosis associated with endoplasmic reticulum stress. *Dis Model Mech.* 2017;10(6):773-86.
27. Herlitz LC, D'Agati VD, Markowitz GS. Crystalline nephropathies. *Arch Pathol Lab Med.* 2012;136(7):713-20.
28. Pizzolato P. Histochemical Recognition of Calcium Oxalate. *J Histochem Cytochem.* 1964;12:333-6.
29. Ogbureke KU, Fisher LW. Expression of SIBLINGs and their partner MMPs in salivary glands. *J Dent Res.* 2004;83(9):664-70.
30. Ronaghi M, Uhlen M, Nyren P. A sequencing method based on real-time pyrophosphate. *Science.* 1998;281(5375):363, 5.
31. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics.* 2009;25(14):1754-60.
32. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. *Nat Genet.* 2011;43(5):491-8.
33. Simon MM, Mallon AM, Howell GR, Reinholdt LG. High throughput sequencing approaches to mutation discovery in the mouse. *Mamm Genome.* 2012;23(9-10):499-513.

34. Keane TM, Goodstadt L, Danecek P, White MA, Wong K, Yalcin B, et al. Mouse genomic variation and its effect on phenotypes and gene regulation. *Nature*. 2011;477(7364):289-94.
35. Grant JR, Arantes AS, Liao X, Stothard P. In-depth annotation of SNPs arising from resequencing projects using NGS-SNP. *Bioinformatics*. 2011;27(16):2300-1.
36. Newey PJ, Gorvin CM, Cleland SJ, Willberg CB, Bridge M, Azharuddin M, et al. Mutant prolactin receptor and familial hyperprolactinemia. *N Engl J Med*. 2013;369(21):2012-20.
37. Schwarz JM, Cooper DN, Schuelke M, Seelow D. MutationTaster2: mutation prediction for the deep-sequencing age. *Nat Methods*. 2014;11(4):361-2.
38. Wu ZJ, Irizarry RA, Gentleman R, Martinez-Murillo F, Spencer F. A model-based background adjustment for oligonucleotide expression arrays. *J Am Stat Assoc*. 2004;99(468):909-17.
39. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate - a Practical and Powerful Approach to Multiple Testing. *J Roy Stat Soc B Met*. 1995;57(1):289-300.
40. Gorvin CM, Wilmer MJ, Piret SE, Harding B, van den Heuvel LP, Wrong O, et al. Receptor-mediated endocytosis and endosomal acidification is impaired in proximal tubule epithelial cells of Dent disease patients. *Proceedings of the National Academy of Sciences of the United States of America*. 2013;110(17):7014-9.
41. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. *Nucleic Acids Res*. 2001;29(9):e45.
42. Eaton GJ, Custer RP, Johnson FN, Stabenow KT. Dystrophic cardiac calcinosis in mice: genetic, hormonal, and dietary influences. *Am J Pathol*. 1978;90(1):173-86.
43. Morrissey R. Renal Calcifications, Mouse. In: Jones TC, editor. *Urinary System*: Springer; 1986. p. 361-4.
44. Evan AP, Coe FL, Lingeman JE, Shao Y, Sommer AJ, Bledsoe SB, et al. Mechanism of formation of human calcium oxalate renal stones on Randall's plaque. *Anat Rec (Hoboken)*. 2007;290(10):1315-23.
45. Evan AP, Coe FL, Rittling SR, Bledsoe SM, Shao Y, Lingeman JE, et al. Apatite plaque particles in inner medulla of kidneys of calcium oxalate stone formers: osteopontin localization. *Kidney Int*. 2005;68(1):145-54.
46. Evan A, Lingeman J, Coe FL, Worcester E. Randall's plaque: pathogenesis and role in calcium oxalate nephrolithiasis. *Kidney Int*. 2006;69(8):1313-8.
47. Taylor ER, Stoller ML. Vascular theory of the formation of Randall plaques. *Urolithiasis*. 2015;43 Suppl 1:41-5.
48. Taguchi K, Hamamoto S, Okada A, Unno R, Kamisawa H, Naiki T, et al. Genome-Wide Gene Expression Profiling of Randall's Plaques in Calcium Oxalate Stone Formers. *Journal of the American Society of Nephrology : JASN*. 2017;28(1):333-47.
49. Fairfield H, Gilbert GJ, Barter M, Corrigan RR, Curtain M, Ding Y, et al. Mutation discovery in mice by whole exome sequencing. *Genome Biol*. 2011;12(9):R86.

50. Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, et al. Analysis of protein-coding genetic variation in 60,706 humans. *Nature*. 2016;536(7616):285-91.
51. Devaiah BN, Geronne A, Singer DS. Bromodomain 4: a cellular Swiss army knife. *J Leukoc Biol*. 2016;100(4):679-86.
52. Devaiah BN, Case-Borden C, Geronne A, Hsu CH, Chen Q, Meerzaman D, et al. BRD4 is a histone acetyltransferase that evicts nucleosomes from chromatin. *Nat Struct Mol Biol*. 2016;23(6):540-8.
53. Fujisawa T, Filippakopoulos P. Functions of bromodomain-containing proteins and their roles in homeostasis and cancer. *Nat Rev Mol Cell Biol*. 2017;18(4):246-62.
54. Crowe BL, Larue RC, Yuan C, Hess S, Kvaratskhelia M, Foster MP. Structure of the Brd4 ET domain bound to a C-terminal motif from gamma-retroviral integrases reveals a conserved mechanism of interaction. *Proceedings of the National Academy of Sciences of the United States of America*. 2016;113(8):2086-91.
55. Jung M, Philpott M, Muller S, Schulze J, Badock V, Eberspacher U, et al. Affinity map of bromodomain protein 4 (BRD4) interactions with the histone H4 tail and the small molecule inhibitor JQ1. *J Biol Chem*. 2014;289(13):9304-19.
56. Sayer JA, Carr G, Simmons NL. Nephrocalcinosis: molecular insights into calcium precipitation within the kidney. *Clin Sci (Lond)*. 2004;106(6):549-61.
57. Osellame LD, Blacker TS, Duchon MR. Cellular and molecular mechanisms of mitochondrial function. *Best Pract Res Clin Endocrinol Metab*. 2012;26(6):711-23.
58. Noh KM, Hwang JY, Follenzi A, Athanasiadou R, Miyawaki T, Grealley JM, et al. Repressor element-1 silencing transcription factor (REST)-dependent epigenetic remodeling is critical to ischemia-induced neuronal death. *Proceedings of the National Academy of Sciences of the United States of America*. 2012;109(16):E962-71.
59. Kleinman JG, Sorokina EA, Wesson JA. Induction of apoptosis with cisplatin enhances calcium oxalate crystal adherence to inner medullary collecting duct cells. *Urol Res*. 2010;38(2):97-104.
60. Tsujihata M, Momohara C, Yoshioka I, Tsujimura A, Nonomura N, Okuyama A. Atorvastatin inhibits renal crystal retention in a rat stone forming model. *J Urol*. 2008;180(5):2212-7.
61. Lee HJ, Jeong SJ, Lee HJ, Lee EO, Bae H, Lieske JC, et al. 1,2,3,4,6-Penta-O-galloyl-beta-D-glucose reduces renal crystallization and oxidative stress in a hyperoxaluric rat model. *Kidney Int*. 2011;79(5):538-45.
62. Kaissling B, Hegyi I, Loffing J, Le Hir M. Morphology of interstitial cells in the healthy kidney. *Anat Embryol (Berl)*. 1996;193(4):303-18.
63. Mo L, Liaw L, Evan AP, Sommer AJ, Lieske JC, Wu XR. Renal calcinosis and stone formation in mice lacking osteopontin, Tamm-Horsfall protein, or both. *American journal of physiology Renal physiology*. 2007;293(6):F1935-43.
64. Mo L, Huang HY, Zhu XH, Shapiro E, Hasty DL, Wu XR. Tamm-Horsfall protein is a critical renal defense factor protecting against calcium oxalate crystal formation. *Kidney Int*. 2004;66(3):1159-66.

65. Shenolikar S, Voltz JW, Minkoff CM, Wade JB, Weinman EJ. Targeted disruption of the mouse NHERF-1 gene promotes internalization of proximal tubule sodium-phosphate cotransporter type IIa and renal phosphate wasting. *Proceedings of the National Academy of Sciences of the United States of America*. 2002;99(17):11470-5.
66. Miyazawa K, Suzuki K, Ikeda R, Moriyama MT, Ueda Y, Katsuda S. Apoptosis and its related genes in renal epithelial cells of the stone-forming rat. *Urol Res*. 2005;33(1):31-8.
67. Aihara K, Byer KJ, Khan SR. Calcium phosphate-induced renal epithelial injury and stone formation: involvement of reactive oxygen species. *Kidney Int*. 2003;64(4):1283-91.
68. Khan SR. Role of renal epithelial cells in the initiation of calcium oxalate stones. *Nephron Exp Nephrol*. 2004;98(2):e55-60.
69. Boehning D, Patterson RL, Sedaghat L, Glebova NO, Kurosaki T, Snyder SH. Cytochrome c binds to inositol (1,4,5) trisphosphate receptors, amplifying calcium-dependent apoptosis. *Nat Cell Biol*. 2003;5(12):1051-61.

TABLES

Table

1

Genotype	Generation	Renal Papillary Calcification	
		Present	Absent
<i>Brd4</i> ^{+/<i>M149T</i>}	G2	50 (66%)	26 (34%)
	G3	11 (65%)	6 (35%)
	G4	13 (100%)	0 (0%)
	G5	10 (83%)	2 (17%)
<i>Brd4</i> ^{+/+}	G2	20 (26%)	56 (74%)
	G3	8 (18%)	37 (82%)
	G4	5 (28%)	13 (72%)
	G5	3 (7%)	40 (93%)

Co-segregation of *Brd4*^{+/*M149T*} variant in RCALC1 mice

The co-segregation of the *Brd4*^{+/*M149T*} variant with renal calcification was investigated in four generations (G2-G5) of the RCALC1 mice. The *Brd4* mutation co-segregated with the renal papillary calcification phenotype observed in RCALC1 mice over four generations. Between 72-93% of *Brd4*^{+/+} mice did not have renal papillary calcification.

Table 2 Plasma biochemical studies of *Brd4*^{+/*M149T*} mice

	Male		Female	
	<i>Brd4</i> ^{+/<i>+</i>} n=15	<i>Brd4</i> ^{+/<i>M149T</i>} n=5	<i>Brd4</i> ^{+/<i>+</i>} n=14	<i>Brd4</i> ^{+/<i>M149T</i>} n=7
Sodium (mmol/L)	155±3.3	154±1.1	152±2.3	151±2.4
Potassium (mmol/L)	7.26±0.9	7.52±1.5	7.33±0.8	6.91±0.8
Calcium (mmol/L) ^a	2.43±0.2	2.35±0.1	2.46±0.1	2.35±0.1
Chloride (mmol/L)	115±3.3	115±1.5	115±2.5	115±2.0
Urea (mmol/L)	11.4±1.8	11.4±1.7	8.41±2.2	9.65±0.9
Creatinine (µmol/L)	31.9±2.2	30.2±1.9	33.0±2.7	31.4±2.2
Glucose (mmol/L)	7.49±1.6	7.78±1.5	8.62±0.5	9.52±0.7
Phosphate (mmol/L)	2.15±0.5	2.01±0.6	2.40±0.6	1.79±0.4
ALP (U/L)	59.7±15.6	64.2±9.6	101.8±20.5	93.0±14.8
PTH (ng/mL)	52.5±7.8	36.4 ^b	20.2±4.4	16.7±6.8
25OHD (ng/mL)	43.0±2.4	32.5 ^b	42.5±1.5	40.4±3.0
P1NP (ng/mL)	23.1±1.5	22.1 ^b	25.9±2.1	20.2±2.0

Plasma biochemical analysis was performed on 16-week-old wild-type (*Brd4*^{+/*+*}) and RCALC1 (*Brd4*^{+/*M149T*}) mice. All values are expressed as mean±SD. ALP = alkaline phosphatase activity. ^aPlasma calcium concentrations were adjusted for the plasma albumin concentration. ^bPlasma biochemistry was obtained from n=3 male *Brd4*^{+/*M149T*} mice. Mean values are shown in Table 2. All values from male *Brd4*^{+/*M149T*} mice are within 2SD of the mean values for male WT mice. The individual values from male *Brd4*^{+/*M149T*} mice are as follows: PTH - 34.3, 20.5 and 54.3 ng/mL; 25OHD - 29.5, 30.5 and 37.4 ng/mL; P1NP - 22.2, 25.0 and 19.2 ng/mL.


Table 3 Urine biochemical studies of *Brd4*^{+/*M149T*} mice

	Male		Female	
	<i>Brd4</i> ^{+/<i>+</i>}	<i>Brd4</i> ^{+/<i>M149T</i>}	<i>Brd4</i> ^{+/<i>+</i>}	<i>Brd4</i> ^{+/<i>M149T</i>}
Urine output (ml/24 hr)	n=10-15 2.35±1.03	n=4 2.63±1.98	n=10-14 2.16±2.03	n=5-7 1.84±0.53
pH	6.96±0.60	7.07±0.42	6.74±0.77	6.37±0.24
Calcium (µmol/24hr)	0.67±0.41	0.58±0.59	1.64±0.65	1.22±0.33
Phosphate (mmol/24hr)	0.06±0.03	0.10±0.02	0.09±0.02	0.09±0.02
Magnesium (µmol/24hr)	19.3±7.8	11.5±11.2	31.9±18.4	39±8.9
Urate (µmol/24hr)	0.51±0.14	0.48±0.12	0.48±0.14	0.73±0.43
Citrate (nmol/24hr)	5.2±3.3	3.0±1.4	2.6±0.6	2.7±0.9
Sodium (mmol/24hr)	0.32±0.05	0.28±0.04	0.41±0.07	0.44±0.08
Potassium (mmol/24hr)	0.58±0.09	0.47±0.06	0.75±0.10	0.80±0.10
CTx (µg/24hr)	0.21±0.08	0.16±0.08	0.68±0.20	0.48±0.20
Creatinine (µmol/24hr)	7.3±1.3	6.4±1.0	10.0±0.9	10.4±2.8
Protein (mg/dl)	735.18±247.1	884.36±389.2	341.40±179.6	395.3±158.1

Urine biochemical analysis was performed on 16-week-old wild-type (*Brd4*^{+/*+*}) and RCALC1 (*Brd4*^{+/*M149T*}) mice, in metabolic cages, using urine samples collected over a 24-hour period. All values are expressed as mean±SD.

FIGURE LEGENDS


Fig. 1. Identification and characterization of RCALC1 mice



(A) Radiograph of the 12-month old G1 founder male mouse showing renal opacity (arrow). Inset, an enlarged image of the renal opacity. (B-C) Presence of renal calcification (brown) in (B) the cortex and (C) the interstitial regions of the renal papilla in kidney sections of G2 offspring, of the G1 founder male stained by von Kossa. (D-E) Renal calcification (brown) in (D) the cortex and (E) the collecting duct cells in kidney sections of wild-type (WT) C3H/HeH inbred mice, stained by von Kossa. (F-M) Immunofluorescence and von Kossa staining of serial sections of kidneys from an

RCALC1 mouse and an unaffected WT littermate. **(F-I)** Osteopontin (OPN) and von Kossa staining, showing colocalization of OPN staining (green, white arrows) with areas of interstitial calcification in RCALC1 mice (black arrows), that was not observed to occur in WT mice. **(J-M)** Tamm-Horsfall protein (THP) and von Kossa staining, showing the presence of THP (orange, asterisks) in renal thick ascending limbs of RCALC1 and WT mice. THP immunostaining and von Kossa staining, corresponding to interstitial calcification, colocalize (arrow) in RCALC1 mice. Scale bars = 50 μ m.


Figure 2. Identification of the *Brd4*-Met149Thr mutation in RCALC1 mice



(A) Haplotype analysis of 51 G2 mice. Each box represents the genotype for the polymorphic locus. Filled box, BALB/c allele; open box, C3H allele. The number of mice that had each haplotype is indicated below each column. Analysis localized the *RCALC1* locus to a ~15Mbp region on mouse chromosome 17, flanked by *rs33663699* and *D17Mit51*. (B) DNA sequence analysis of *Brd4* in DNA extracted from an unaffected (wildtype, WT) and an RCALC1 mouse (mutant) confirmed the whole-exome analysis result of a heterozygous T-to-C transition in codon 149 in RCALC1 mice, that was predicted to result in a missense change of a WT methionine (Met, M) to a mutant threonine (Thr, T). (C) Multiple protein-sequence alignment of residues comprising the α AZ, α A, α B and α C helices that form bromodomain 1 (BD1) of BRD4 in five species. Conserved residues are shown in gray, and WT (Met, M) and mutant (Thr, T) residues in red. (D) Domain structure of human BRD4 protein, which comprises two bromodomains


(BD1 and BD2), an extraterminal (ET) domain and a carboxy-terminal motif (CTM). **(E)** Structure of the human BRD4 bromodomain 1 (PDB:5LRQ) with Met149 indicated in blue. **(F)** Close-up view of the wild-type Met149 residue showing backbone polar contacts with three residues, Asp146, Ala152 and Leu153. **(G)** The mutant Thr149 (purple) retains these contacts, but forms an additional contact with residue Asp145, which may reduce flexibility of the BRD4 protein, and thereby affect its function.

Figure 3. Analysis of Differentially Expressed Genes by qRT-PCR



(A-D) Validation of differentially expressed genes from cDNA expression profiling analysis of kidneys from wild-type (*Brd4*^{+/+}) and RCALC1 (*Brd4*^{+/M149T}) mice by qRT-PCR analysis. Renal expression of: (A) *Cyp24a1*, (B) *Gc*, (C) *Id1*, and (D) *Id3*, in cDNA from *Brd4*^{+/+} and *Brd4*^{+/M149T} mice. N=4-6 mice per group. Data was normalized to geometric mean of 3 housekeeper genes (*Ccnd1*, *Ccnd2*, *Gapdh*) and expressed as a fold-change relative to *Brd4*^{+/+}, set at 1. Histograms are presented as mean±SEM. Statistical analyses were performed by Student's t-test, *p<0.05, **p<0.02, compared to *Brd4*^{+/+}.

Fig. 4 Analysis of apoptosis in *Brd4*^{+/*M149T*} mice



(A-B) Validation of differentially expressed genes involved in apoptosis from cDNA expression profiling analysis of kidneys from wild-type (*Brd4*^{+/+}) and RCALC1 (*Brd4*^{+/*M149T*}) mice by qRT-PCR analysis. Renal expression of: (A) *Casp3* and (B) *Csrnp3* genes, in kidney cDNA from *Brd4*^{+/+} and *Brd4*^{+/*M149T*} mice. N=4-6 mice for each group. Data was normalized to the geometric mean of three housekeeper genes (*Ccnd1*, *Ccnd2*, *Gapdh*) and expressed as a fold-change relative to *Brd4*^{+/+}, set at 1. Histograms are presented as mean±SEM. Statistical analyses were performed by Student's t-test, *p<0.05, **p<0.02, compared to *Brd4*^{+/+}. (C-D) TUNEL and (E-F) von Kossa staining showing apoptotic nuclei (green) in areas corresponding to interstitial calcification in RCALC1 (*Brd4*^{+/*M149T*}) mice (arrows) and in control wild-type (WT) *Brd4*^{+/+} mice. Nuclei were counterstained with nuclear fast red for von Kossa staining and DAPI (blue) for immunofluorescence. Scale bars = 50µm.